What is olfactory neuroblastoma?

olfactory neuroblastoma, also called Esthesioneuroblastoma, is a very malignant or cancer tumor, which is expected to come from olfactory cells. For the purpose of the fragrance, olfactory cells are responsible, located in the upper back of the nose. OLFACTORY neuroblastoma often responds well to radiation therapy, but the tumor has a high tendency to repeat after excision.

olfactory neuroblastoma is relatively rare cancer. Cancer was first characterized in 1924 and less than 1,000 cases have been recorded since then. Olfactory neuroblastoma can cause loss of aroma, taste and vision, as well as the disfigure of the face in advanced cases.

Through its name, olfactory neuroblastoma is considered to be different from other neuroblastomas because it does not come in the sympathetic nervous system (SNS). The condition is controversial because it is so rare that it cannot be easily studied and characterized. Some cases of Esthesioneuroblastoma are extreagresive, resulting in death within a few mechoes while others grow slowly. Some patients survived for 20 years with olfactory neuroblastoma. No trends were discovered in terms of the tendency of Esthesioneublastoma to influence the individuals of a certain race, gender or age, and the tumor does not seem to run in families.

6 The nasal symptoms include nasal obstruction, discharge and polyps. Symptoms of the face include swelling, pain and lack of feeling. Oral symptoms include relaxed teeth and tooth loss, as well as ulcers in the mouth. Symptoms may occur as a loss of vision, while the problems of the cervix are present as a mass in the throat. The most common are nasal symptoms and usually appear first.

olfactory neuroblastoma is diagnosed by observing symptoms, followed by biopsy or displaying, such as scanning computer tomography (CT) or displaying magnetic resonance (MRI). Usually they are treated by surgery, followed byradiation. Chemotherapy is not common in the treatment of esthesioneuroblastoma.

Surgical treatment of esthesioneuroblastoma, like all operations, has risks. This includes infections, meningitis, pneumocephalus and blindness. There are 10-15% of the development of one of these complications and patients undergoing surgery for Esthesionneublastoma have a five-year survival rate of 50-80%. The patient should be able to leave the hospital the day after surgery and does not require extensive follow -up care, but because of the tumor tendency, lengthy monitoring, sometimes years after surgery, is required.